Mostrar el registro sencillo del ítem

dc.contributor.author
Acosta, Patricio Leandro
dc.contributor.author
Caballero, Mauricio Tomás
dc.contributor.author
Polack, Fernando Pedro
dc.date.available
2020-06-30T14:35:00Z
dc.date.issued
2015-12
dc.identifier.citation
Acosta, Patricio Leandro; Caballero, Mauricio Tomás; Polack, Fernando Pedro; Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease; American Society for Microbiology; Clinical and Vaccine Immunology; 12-2015; 1-7
dc.identifier.issn
1556-6811
dc.identifier.uri
http://hdl.handle.net/11336/108494
dc.description.abstract
In 1967, infants and toddlers immunized with a formalin-inactivated vaccine against respiratory syncytial virus (RSV) experienced an enhanced form of RSV disease characterized by high fever, bronchopneumonia, and wheezing when they became infected with wild-type virus in the community. Hospitalizations were frequent, and two immunized toddlers died upon infection with wild-type RSV. The enhanced disease was initially characterized as a "peribronchiolar monocytic infiltration with some excess in eosinophils." Decades of research defined enhanced RSV disease (ERD) as the result of immunization with antigens not processed in the cytoplasm, resulting in a nonprotective antibody response and CD4(+) T helper priming in the absence of cytotoxic T lymphocytes. This response to vaccination led to a pathogenic Th2 memory response with eosinophil and immune complex deposition in the lungs after RSV infection. In recent years, the field of RSV experienced significant changes. Numerous vaccine candidates with novel designs and formulations are approaching clinical trials, defying our previous understanding of favorable parameters for ERD. This review provides a succinct analysis of these parameters and explores criteria for assessing the risk of ERD in new vaccine candidates.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
American Society for Microbiology
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
RESPIRATORY SYNCYTIAL VIRUS
dc.subject
VACCINE
dc.subject.classification
Enfermedades Infecciosas
dc.subject.classification
Ciencias de la Salud
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
dc.title
Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2020-06-29T16:26:43Z
dc.journal.pagination
1-7
dc.journal.pais
Estados Unidos
dc.journal.ciudad
Washington
dc.journal.title
Clinical and Vaccine Immunology
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1128/CVI.00609-15
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://cvi.asm.org/content/23/3/189


Archivos asociados

 

Comunidades y colecciones

Mostrar el registro sencillo del ítem